Bispecific Antibodies in the Treatment of Multiple Myeloma
An expert oncologist evaluates the effect of combination trials of bispecific antibodies on the multiple myeloma treatment landscape.
An expert oncologist evaluates the effect of combination trials of bispecific antibodies on the multiple myeloma treatment landscape.
MISSOURI (KSNF) — One university in the Show-Me State receives high marks on a global scale. Washington University in St. Louis (WUSTL) is ranked 8th…
Study in Blood dissecting the role of NFκB signaling effectors in MPN disease biology Stephen T. Oh, MD, PhD, Co-Chief and Associate Professor of Medicine,…
Herbicide and pesticide exposure [e.g., agent orange (AO)] is associated with an increased risk of multiple myeloma (MM) due to the contaminant, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). However,…
ST. LOUIS – The St. Louis Blues are preparing to recognize the 25th Anniversary of the National Hockey League’s fight against cancer when they host…
While the flesh-eating undead portrayed on television are just fiction, there are clear examples of parasites that have evolved to manipulate their hosts, according to…
The decision by an advisory committee may lead to Food and Drug Administration approval of the first treatment for humans that uses the CRISPR gene-editing…
Adding TPST-1120 to atezolizumab and bevacizumab appears to improve progression-free survival compared with atezolizumab and bevacizumab alone in patients with hepatocellular carcinoma.
Sara M. Tolaney, MD, MPH, discusses the evolving role of Ki-67 and circulating tumor DNA as prognostic or predictive biomarkers in breast cancer.
This Viewpoint discusses the unfairness of current CAR T-cell therapy allocation practices and offers alternative methods to more fairly allocate therapy.